Last $0.28 USD
Change Today +0.0161 / 6.22%
Volume 10.6K
OMBP On Other Exchanges
Symbol
Exchange
OTC BB
As of 9:34 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

omni bio pharmaceutical inc (OMBP) Snapshot

Open
$0.27
Previous Close
$0.26
Day High
$0.28
Day Low
$0.27
52 Week High
01/24/14 - $0.50
52 Week Low
10/11/13 - $0.12
Market Cap
10.7M
Average Volume 10 Days
17.8K
EPS TTM
$-0.14
Shares Outstanding
38.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OMNI BIO PHARMACEUTICAL INC (OMBP)

Related News

No related news articles were found.

omni bio pharmaceutical inc (OMBP) Related Businessweek News

No Related Businessweek News Found

omni bio pharmaceutical inc (OMBP) Details

Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado.

1 Employees
Last Reported Date: 06/16/14
Founded in 2006

omni bio pharmaceutical inc (OMBP) Top Compensated Officers

Chairman, Chief Executive Officer and Chief F...
Total Annual Compensation: $180.0K
Chief Scientific Officer and Member of Scient...
Total Annual Compensation: $90.0K
Compensation as of Fiscal Year 2014.

omni bio pharmaceutical inc (OMBP) Key Developments

Omni Bio Pharmaceutical, Inc. Appoints Jack Riccardi as Chief Financial Officer, with Effective from September 1, 2014

Omni Bio Pharmaceutical, Inc. announced the appointment of Jack Riccardi as its Chief Financial Officer. Mr. Riccardi brings more than 30 years of financial leadership experience. He was formerly CFO of ADial Pharmaceuticals and served most recently as CFO and Partner at Green Street Ventures. Mr. Riccardi's appointment will become effective on September 1, 2014. Prior to his role at Green Street Ventures, Mr. Riccardi served as Chief Financial Officer, Treasurer and Secretary of ADial Pharmaceuticals, where he oversaw the commercialization effort, drug market studies, and advanced valuation analyses for several late stage pharmacotherapies. He also served as Chief Financial Officer of Modern Visuals, a software start-up venture spun off from Siemens Technology Group, where he successfully prepared the company for its eventual sale to a strategic buyer. Mr. Riccardi spent eight years at General Motors, last serving as Director, Strategic Planning. While at GM, Jack initiated content acquisition and strategic alliance efforts expanding GM's OnStar brand into new household markets, established the company's corporate technology venture fund for direct investment into promising technologies, and founded the company's Business Development Forum.

Omni Bio Pharmaceutical, Inc. Auditor Raises 'Going Concern' Doubt

Omni Bio Pharmaceutical, Inc. filed its 10-K on Jun 16, 2014 for the period ending Mar 31, 2014. In this report its auditor, Hein & Associates LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Omni Bio Pharmaceutical, Inc. Appoints Bruce D. Forrest as Chief Development Officer

Omni Bio Pharmaceutical, Inc. announced the appointment of Dr. Bruce D. Forrest to the position of Chief Development Officer. Dr. Forrest is currently President of B D Forrest & Company, Inc. Dr. Forrest has been retained over the past 18 months by Omni Bio to assist the company with such services. In his expanded role of Chief Development Officer he will now also oversee implementation of the development plan for Omni Bio's lead Fc fusion recombinant AAT molecule that is being targeted for the treatment of Type 1 diabetes, graft versus host disease and various inflammatory conditions, including chronic gout. Included in this role will be interface and leadership responsibilities for work being performed by recently engaged cell line optimization and product manufacturing partner, Gallus BioPharmaceuticals, Inc. Dr. Forrest has over 25 years of industry experience in pharmaceutical development, including vaccines and biopharmaceuticals. Dr. Forrest was previously Senior Vice President in Vaccines R&D at Wyeth Pharmaceuticals where he was responsible for clinical and development activities for all late phase programs.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMBP:US $0.28 USD +0.0161

OMBP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMBP.
View Industry Companies
 

Industry Analysis

OMBP

Industry Average

Valuation OMBP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMNI BIO PHARMACEUTICAL INC, please visit www.omnibiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.